BioSpace News Archive

As a Board Member of MAPS Canada and with extended training and experience in the application of Ketamine-Assisted Psychotherapy, Dr. Bhayana is at the forefront of psychedelic medicine research and advancement, directing his expertise and medical background toward the future-medicalization of psychedelic-assisted psychotherapy with an emphasis on best practices, ethics, and accessibility.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial. IMPALA-2 is a Phase 3 trial designed to evaluate the efficacy and safety of molgramostim compared to placebo.

Neuroelectrics, a clinical-stage company pioneering brain stimulation therapies, has been granted FDA Breakthrough Device Designation for its Starstim® neuromodulation platform in refractory focal epilepsy.

The Philadelphia County Medical Society has awarded N. Scott Adzick, MD, Surgeon-in-Chief at Children’s Hospital of Philadelphia, the 2021 Strittmatter Award, its most prestigious scientific honor.

Everads Therapy, a life sciences company developing a novel and differentiated suprachoroidal delivery technology for facilitating treatment of retinal diseases, announced today that a clinical-stage gene therapy company has entered into a collaboration to evaluate suprachoroidal delivery for its gene therapy pipeline programs using Everads’ delivery platform.

Scientists from The Feinstein Institutes for Medical Research today announced the publication of results from a phase 3 clinical trial looking at the safety and efficacy of the oral neuroactive steroid zuranolone (30mg) in the treatment of patients with postpartum depression (PPD).

Predictive Health Diagnostics Company, Inc. announced that its Clinical Laboratory Improvement Amendments certified laboratory, Morningstar Laboratories is experiencing strong gains in in-network provider participation and that the laboratory has achieved accreditation from the College of American Pathologists.

Codagenix Inc., a clinical-stage synthetic biology company pioneering a novel platform for vaccines and oncolytic virus therapies, today announced preclinical data published in the Proceedings of the National Academy of Science (PNAS) supporting the potential safety and efficacy of COVI-VAC, the company’s intranasal live-attenuated COVID-19 vaccine

POINT Biopharma Inc. (“POINT”), a company accelerating the discovery, development and global access to radiopharmaceuticals, today announced the completion of its business combination with Therapeutics Acquisition Corp., d/b/a Research Alliance Corp. I (Nasdaq: RACA) (“RACA”), a special purpose acquisition company (“SPAC”), sponsored by RA Capital Management.

Freeline Therapeutics Holdings plc announced the expansion of its executive leadership team with the appointment of James “Jay” Bircher as Chief Technical Operations Officer effective July 1, 2021.